Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simvastatin improves diabetes-induced coronary endothelial dysfunction.

Huda E Tawfik1, Azza B El-Remessy, Suraporn Matragoon

  • 1Department of Pharmacology and Toxicology, Medical College of Georgia, 1120 15th Street, CB-3624, Augusta, GA 30912, USA.

The Journal of Pharmacology and Experimental Therapeutics
|July 20, 2006
PubMed
Summary

Simvastatin (SIM) improves coronary artery function in diabetic rats by reducing oxidative stress and increasing nitric oxide (NO) bioavailability. This statin therapy offers a potential mechanism for decreasing cardiovascular risk in diabetes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sigma 1 Receptor Activation Coordinates Metabolic Stress Responses to Protect Retinal Vasculature in Ischemic Retinopathy.

Investigative ophthalmology & visual science·2026
Same author

Endothelial Drp1 integrates VEGF-induced redox signaling with glycolysis through cysteine oxidation to drive angiogenesis.

Nature communications·2026
Same author

Novel Role of AcylCoA:cholesterol acyltransferase 1 (ACAT1/SOAT1) in Diabetic Retinopathy.

bioRxiv : the preprint server for biology·2025
Same author

Inhibition of pathological angiogenesis in oxygen-induced retinopathy by arginine depletion with ADI-PEG20.

Experimental eye research·2025
Same author

Novel Role of Copper Transporter CTR1 and Therapeutic Potential of Copper Chelators in Retinal Ischemia-Reperfusion Injury.

Investigative ophthalmology & visual science·2025
Same author

Myeloid ACAT1/SOAT1: a novel regulator of dyslipidemia and retinal neovascularization.

npj metabolic health and disease·2025

Area of Science:

  • Cardiovascular Pharmacology
  • Endothelial Function
  • Diabetic Complications

Background:

  • 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors (statins) reduce cardiovascular events in diabetic patients, but the underlying mechanisms remain unclear.
  • Diabetic patients exhibit impaired coronary vasodilation and increased oxidative stress, contributing to cardiovascular morbidity.
  • Endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability, is a key feature of diabetic cardiovascular complications.

Purpose of the Study:

  • To investigate the effects of simvastatin (SIM) on NO bioavailability and oxidative stress in the coronary vasculature of diabetic rats.
  • To elucidate the cellular mechanisms by which SIM improves endothelial function in the context of diabetes.

Main Methods:

  • Assessment of acetylcholine (ACh)-mediated vasorelaxation in coronary arteries from diabetic and control rats.

Related Experiment Videos

  • Quantification of oxidative stress using dichlorofluorescein (DCF) imaging and nitrotyrosine labeling.
  • Measurement of trans-coronary uptake of L-arginine and NO levels in cell culture media and plasma.
  • Evaluation of endothelial NO synthase (eNOS) protein levels and reactive oxygen species (ROS) production in rat coronary artery endothelial cells (RCAEC).

    • Main Results:

    • Diabetes significantly impaired coronary vasorelaxation and increased oxidative stress markers (DCF, nitrotyrosine) and reduced L-arginine uptake.
    • Simvastatin (SIM) treatment improved ACh-mediated vasorelaxation in diabetic rat coronary arteries.
    • SIM treatment reduced oxidative stress markers, increased eNOS protein levels, and restored normal NO levels in diabetic vessels and high-glucose-exposed RCAEC.
    • SIM's beneficial effects were linked to the inhibition of NADPH oxidase and reduction of ROS/superoxide formation.

    Conclusions:

    • Simvastatin ameliorates diabetes-induced coronary dysfunction by enhancing NO bioavailability and mitigating oxidative stress.
    • The findings suggest that SIM's protective effects in diabetic cardiovascular disease involve the restoration of endothelial function through antioxidant and NO-enhancing mechanisms.